Paradigm Biopharmaceuticals (ASX:PAR)

ASX announcement history & article coverage

29
Total announcements
(in last 3 months)
4
With article
25
No article
Article coverage
14%
Transparent by design. Announcments by Paradigm Biopharmaceuticals (ASX:PAR) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.

28 Aug 2026 · 12:59 pm AEST ASX Filing
Appendix 4G and Corporate Governance Statement
28 Aug 2026 · 12:47 pm AEST ⚡ Price SensitiveMaterial ASX Filing
Appendix 4E and 2026 Annual Report
Paradigm completes Phase 3 recruitment, raises A$21.74m, reports $56.3m loss, eyes key clinical milestones
25 Aug 2026 · 06:03 pm AEST ASX Filing
Application for quotation of securities - PAR
13 Aug 2026 · 09:33 am AEST ASX Filing
80% Safety Review Complete, September IA on Track

30 July 2026 · 04:56 pm AEST ASX Filing
Application for quotation of securities - PAR
30 July 2026 · 09:55 am AEST ⚡ Price SensitiveMaterial ASX Filing
June 2026 Quarterly Activities Report & Appendix 4C
Paradigm completes Phase 3 enrolment, raises A$21.38 million, targets Interim Analysis in September 2026
27 July 2026 · 08:17 am AEST ASX Filing
Notification of cessation of securities - PAR
22 July 2026 · 08:18 am AEST ⚡ Price SensitiveMaterial ASX Filing
Paradigm Receives $5.75m R&D Tax Incentive Refund
Paradigm secures $5.75 million in Australian Government R&D tax refunds to support Phase 3 osteoarthritis program
17 July 2026 · 06:51 pm AEST ASX Filing
Application for quotation of securities - PAR
13 July 2026 · 01:32 pm AEST ASX Filing
Notice under Section 708A
13 July 2026 · 01:21 pm AEST ASX Filing
Notification regarding unquoted securities - PAR
13 July 2026 · 01:14 pm AEST ⚡ Price SensitiveMaterial ASX Filing
Drawdown of Tranche 4 under the Convertible Note Facility
Paradigm Biopharma completes US$3 million drawdown under Convertible Note Facility to support Phase 3 trial
1 July 2026 · 05:52 pm AEST ASX Filing
Change of Director's Interest Notice

29 June 2026 · 05:01 pm AEST ASX Filing
Notification of cessation of securities - PAR
29 June 2026 · 04:55 pm AEST ASX Filing
Notification of cessation of securities - PAR
18 June 2026 · 05:46 pm AEST ASX Filing
Change of Director's Interest Notice
18 June 2026 · 05:46 pm AEST ASX Filing
Change of Director's Interest Notice
18 June 2026 · 05:29 pm AEST ASX Filing
Application for quotation of securities - PAR
17 June 2026 · 10:52 am AEST ASX Filing
Listing of Options - Top 20 Holders and Distribution Reports
17 June 2026 · 10:50 am AEST ASX Filing
Application for quotation of securities - PAR
15 June 2026 · 09:11 am AEST ⚡ Price SensitiveMaterial ASX Filing
PAR Completes Enrolment in Pivotal Phase 3
Paradigm completes enrolment in Phase 3 osteoarthritis trial, on track for 2027 results
11 June 2026 · 06:29 pm AEST ASX Filing
Options Prospectus
11 June 2026 · 12:56 pm AEST ASX Filing
Results of Meeting
5 June 2026 · 06:34 pm AEST ASX Filing
Change of Director's Interest Notice
5 June 2026 · 06:34 pm AEST ASX Filing
Change of Director's Interest Notice
4 June 2026 · 08:20 am AEST ASX Filing
Ceasing to be a substantial holder
3 June 2026 · 05:34 pm AEST ASX Filing
Notification of cessation of securities - PAR
2 June 2026 · 05:31 pm AEST ASX Filing
Application for quotation of securities - PAR
2 June 2026 · 10:18 am AEST ASX Filing
Application for quotation of securities - PAR